Literature DB >> 23316963

Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Arda Kucukguven1, Raouf A Khalil.   

Abstract

Varicose veins (VVs) are a common venous disease of the lower extremity characterized by incompetent valves, venous reflux, and dilated and tortuous veins. If untreated, VVs could lead to venous thrombosis, thrombophlebitis and chronic venous leg ulcers. Various genetic, hormonal and environmental factors may lead to structural changes in the vein valves and make them incompetent, leading to venous reflux, increased venous pressure and vein wall dilation. Prolonged increases in venous pressure and vein wall tension are thought to increase the expression/activity of matrix metalloproteinases (MMPs). Members of the MMPs family include collagenases, gelatinases, stromelysins, matrilysins, membrane- type MMPs and others. MMPs are known to degrade various components of the extracellular matrix (ECM). MMPs may also affect the endothelium and vascular smooth muscle, causing changes in the vein relaxation and contraction mechanisms. Endothelial cell injury also triggers leukocyte infiltration, activation and inflammation, which lead to further vein wall damage. The vein wall dilation and valve dysfunction, and the MMP activation and superimposed inflammation and fibrosis would lead to progressive venous dilation and VVs formation. Surgical ablation is an effective treatment for VVs, but may be associated with high recurrence rate, and other less invasive approaches that target the cause of the disease are needed. MMP inhibitors including endogenous tissue inhibitors (TIMPs) and pharmacological inhibitors such as zinc chelators, doxycycline, batimastat and marimastat, have been used as diagnostic and therapeutic tools in cancer, autoimmune and cardiovascular disease. However, MMP inhibitors may have side effects especially on the musculoskeletal system. With the advent of new genetic and pharmacological tools, specific MMP inhibitors with fewer undesirable effects could be useful to retard the progression and prevent the recurrence of VVs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23316963      PMCID: PMC3584231     

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  463 in total

1.  Characterization of the role of the "MT-loop": an eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases.

Authors:  W R English; B Holtz; G Vogt; V Knäuper; G Murphy
Journal:  J Biol Chem       Date:  2001-09-12       Impact factor: 5.157

2.  Effect of elastic compression stockings on venous hemodynamics during walking.

Authors:  Veronica Ibegbuna; Konstantinos T Delis; Andrew N Nicolaides; Olayide Aina
Journal:  J Vasc Surg       Date:  2003-02       Impact factor: 4.268

Review 3.  Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement.

Authors:  Alberto Caggiati; John J Bergan; Peter Gloviczki; Gorges Jantet; Colin P Wendell-Smith; Hugo Partsch
Journal:  J Vasc Surg       Date:  2002-08       Impact factor: 4.268

4.  Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo.

Authors:  R Forough; N Koyama; D Hasenstab; H Lea; M Clowes; S T Nikkari; A W Clowes
Journal:  Circ Res       Date:  1996-10       Impact factor: 17.367

5.  Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression.

Authors:  Y Herouy; P Mellios; E Bandemir; S Dichmann; P Nockowski; E Schöpf; J Norgauer
Journal:  J Dermatol Sci       Date:  2001-04       Impact factor: 4.563

6.  Characterization of recombinant pig enamelysin activity and cleavage of recombinant pig and mouse amelogenins.

Authors:  O H Ryu; A G Fincham; C C Hu; C Zhang; Q Qian; J D Bartlett; J P Simmer
Journal:  J Dent Res       Date:  1999-03       Impact factor: 6.116

7.  Four-year follow-up on endovascular radiofrequency obliteration of great saphenous reflux.

Authors:  Robert F Merchant; Olivier Pichot; Kenneth A Myers
Journal:  Dermatol Surg       Date:  2005-02       Impact factor: 3.398

8.  Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases.

Authors:  M Margarida Bernardo; Stephen Brown; Zhi-Hong Li; Rafael Fridman; Shahriar Mobashery
Journal:  J Biol Chem       Date:  2002-01-14       Impact factor: 5.157

9.  Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions.

Authors:  Mira Lischper; Simon Beuck; Gokulan Thanabalasundaram; Christian Pieper; Hans-Joachim Galla
Journal:  Brain Res       Date:  2010-03-01       Impact factor: 3.252

10.  HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins.

Authors:  S Nomura; K Yoshimura; N Akiyama; A Mikamo; A Furutani; H Aoki; M Matsuzaki; K Hamano
Journal:  Eur Surg Res       Date:  2005 Nov-Dec       Impact factor: 1.745

View more
  35 in total

Review 1.  Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.

Authors:  Elisabeth MacColl; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2015-08-28       Impact factor: 4.030

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 3.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

4.  Decreased homodimerization and increased TIMP-1 complexation of uteroplacental and uterine arterial matrix metalloproteinase-9 during hypertension-in-pregnancy.

Authors:  Juanjuan Chen; Zongli Ren; Minglin Zhu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2017-05-12       Impact factor: 5.858

Review 5.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

6.  Increased vascular and uteroplacental matrix metalloproteinase-1 and -7 levels and collagen type I deposition in hypertension in pregnancy: role of TNF-α.

Authors:  Wei Li; Ning Cui; Marc Q Mazzuca; Karina M Mata; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

7.  Fibrotic Venous Remodeling and Nonmaturation of Arteriovenous Fistulas.

Authors:  Laisel Martinez; Juan C Duque; Marwan Tabbara; Angela Paez; Guillermo Selman; Diana R Hernandez; Chad A Sundberg; Jason Chieh Sheng Tey; Yan-Ting Shiu; Alfred K Cheung; Michael Allon; Omaida C Velazquez; Loay H Salman; Roberto I Vazquez-Padron
Journal:  J Am Soc Nephrol       Date:  2018-01-02       Impact factor: 10.121

8.  Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.

Authors:  Zongli Ren; Ning Cui; Minglin Zhu; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-03-23       Impact factor: 4.733

9.  From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases.

Authors:  Raffaele Serra; Luca Gallelli; Lucia Butrico; Gianluca Buffone; Francesco G Caliò; Giovanni De Caridi; Mafalda Massara; Andrea Barbetta; Bruno Amato; Miriam Labonia; Selena Mimmi; Enrico Iaccino; Stefano de Franciscis
Journal:  Int Wound J       Date:  2016-03-15       Impact factor: 3.315

10.  HtrA1 upregulates the expression of ADAMTS-5 in HNPCs via the ERK/NF-κB/JNK signaling pathway.

Authors:  Dapeng Li; Yumin Wu; Yan Wu; Chenlie Ni; Pan Jiang; Jian Li; Lianghao Mao; Qiping Zheng; Jiawei Yue
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.